Kiwi Wealth Investments Limited Partnership’s Regeneron Pharmaceuticals REGN Stock Holding History

Kiwi Wealth Investments Limited Partnership’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-497	Closed	-$359K	–	209
2022 Q4	$359K	Sell	497 -7,984	-94%	-$5.89M	0.02%	193
2022 Q3	$5.01M	Hold	8,481	–	–	0.35%	77
2022 Q2	$5.01M	Sell	8,481 -1,111	-12%	-$722K	0.35%	77
2022 Q1	$6.7M	Sell	9,592 -1,004	-9%	-$635K	0.36%	79
2021 Q4	$6.69M	Sell	10,596 -44	-0.4%	-$27.1K	0.32%	84
2021 Q3	$6.44M	Sell	10,640 -1,751	-14%	-$1.09M	0.33%	77
2021 Q2	$6.92M	Buy	+12,391	New	+$6.28M	0.36%	70
2019 Q2	–	Sell	-2,320	Closed	-$953K	–	206
2019 Q1	$953K	Sell	2,320 -34	-1%	-$14K	0.09%	159
2018 Q4	$879K	Buy	+2,354	New	+$862K	0.09%	158
2015 Q4	–	Sell	-9,715	Closed	-$4.52M	–	121
2015 Q3	$4.52M	Buy	+9,715	New	+$5.22M	0.53%	48

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Kiwi Wealth Investments Limited Partnership's REGN Position: Q1 2023 in Review

Kiwi Wealth Investments Limited Partnership sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 497 shares — an estimated $359K sold.

Kiwi Wealth Investments Limited Partnership first reported a position in REGN in Q3 2015 and held it in 10 quarters. The position peaked at $6.92M in Q2 2021. 1,193 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

Kiwi Wealth Investments Limited Partnership reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Kiwi Wealth Investments Limited Partnership sold 497 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $359K.
Kiwi Wealth Investments Limited Partnership first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 10 quarters.
Kiwi Wealth Investments Limited Partnership's Regeneron Pharmaceuticals position peaked at $6.92M in Q2 2021.
1,193 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Kiwi Wealth Investments Limited Partnership's 13F filing for Q1 2023, filed 16 May 2023.